|
| 1） |
Wirth M, et al:Bicalutamide（Casodex）150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 2001;58:146-51. |
| 2） |
See W, Iversen P, Wirth M, et al. Immediate treatment with bicalutamide 150 mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. Eur Urol. 2003;44（5）:512-7;discussion 517-8. |
| 3） |
Iversen P, Johansson JE, Lodding P, et al. Scandinavian Prostatic Cancer Group . Bicalutamide（150 mg）versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer:5. 3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol. 2004;172（5）:1871-6. |
| 4） |
Akaza H. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. BJU Int. 2004;93（1）:42-6. |
| 5） |
Hachiya T, Minei S, Hirano D, et al. Adjuvant hormone therapy in patients with positive surgical margins after radical prostatectomy. Nippon Hinyokika Gakkai Zasshi. 2002;93（3）:469-75. |
新検索ページはこちら
ログイン
お問い合わせ
書誌情報
引用文献
